Brief: EMA Gets Application For Marketing Authorisation For Regkirona For Treating COVID-19
Oct 4 (Reuters) - European Medicines Agency:
* EMA RECEIVES APPLICATION FOR MARKETING AUTHORISATION FOR
REGKIRONA (REGDANVIMAB) FOR TREATING PATIENTS WITH COVID-19
* EMA SAYS WILL ASSESS THE BENEFITS AND RISKS OF REGKIRONA
UNDER A
REDUCED TIMELINE AND COULD ISSUE AN OPINION WITHIN TWO MONTHS
Further company coverage: 091990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Celltrion Healthcare Co
See all newsBrief: Celltrion USA says Ventegra Will Place FDA-Approved Biosimilar To Avastin , Vegzelma On Its Commercial Formulary As A Preferred Brand
Brief: Celltrion Healthcare To Acquire 92.7 Billion Won Worth Of Own Shares
Brief: Celltrion Healthcare Q3 Operating Profit 50.5 Billion Won, Down 30.4% From Year Earlier
Brief: Celltrion Usa- Announces Distribution And Incorporation Of Yuflyma (Adalimumab-Aaty) To Carepartners Specialty Pharmacy Cost Savings Programs
Brief: Celltrion Healthcare's Merger With Celltrion Approved In Shareholder Meeting -Yonhap